Biogen reports positive two-year data for Alzheimer’s drug
Biogen (BIIB) reported positive two-year data for its experimental Alzheimer’s drug diranersen, showing a 38% slowdown in clinical decline. The Phase 2 study with 416 participants found the 60 mg dose had a 1.09-point treatment difference on CDR-SB compared to placebo. The drug was well-tolerated with no new safety signals. The FDA granted Fast Track designation for diranersen in 2025.
How this was made
The 30-second read
Why it matters
The reported two-year efficacy improvement and absence of new safety signals are the main incremental catalysts, potentially shifting expectations for future trial outcomes and regulatory prospects.
Market read
Traders may reassess BIIB’s clinical probability-weighted valuation after new two-year efficacy data with no new safety signals.
What to watch
The article does not mention effect size consistency across subgroups, biomarker confirmation, or Phase 3 plans/timelines, which are key for translating efficacy into valuation.
Background
Biogen’s diranersen is an investigational antisense oligonucleotide targeting MAPT mRNA to reduce tau production; FDA Fast Track was granted in 2025.
Ticker impact
Biogen says its Phase 2 Alzheimer’s drug diranersen slowed clinical decline by 38% at two years on CDR-SB, with no new safety signals.
Likely upward bias as traders price in improved clinical durability and reduced downside risk from safety concerns.
The article reports specific two-year efficacy deltas (CDR-SB, ADAS-Cog13, iADRS) and states no new safety signals, which are direct inputs to valuation models for Alzheimer’s assets.
Market effects
Reinforces the broader Alzheimer’s tau-targeting narrative and may lift sentiment for other neurodegenerative disease programs, though the impact is likely company-specific.
Primarily US biotech sentiment; limited direct regional spillover beyond healthcare/biopharma flows.
Could modestly affect global investor appetite for Alzheimer’s clinical-stage assets, but no cross-border regulatory decision is reported.
Counterpoint
Phase 2 results may not translate into Phase 3 success, and the placebo-to-extension comparison design can overstate durability versus a fully randomized endpoint.
Key entities
- companyBiogen Inc.
NASDAQ-listed biotech reporting positive two-year Phase 2 data for diranersen in Alzheimer’s.
- drugdiranersen
Investigational antisense oligonucleotide therapy targeting MAPT mRNA to reduce tau production.
- regulatorFDA
Granted Fast Track designation to diranersen in 2025.


